Engineered Fab glycosylation of a blood-brain barrier transporter single-chain variable fragment preserved functionality but did not impact anti-drug antibody formation
Gustaf Hederoth, Jielu Liu, Ana Godec, Nicole G. Metzendorf, Bence Réthi, Greta Hultqvist
This study engineered sialylation on a scFv-based therapeutic to reduce anti-drug antibodies but found no significant impact on immunogenicity or pharmacokinetics in mice.
bioRxiv · Nov 28, 2025 · PreprintBioengineering